These criteria aim to identify individuals with a 5% to 10% probability of carrying BRCA1/BRCA2 PVs,3,4,5 but this misses approximately 50% of PV carriers in individuals with cancer6,7,8 and much higher proportions with population ascertainment.9 Implementation of clinical criteria and FH–based testing is dependent on cancer diagnoses, awareness of importance and accuracy of cancer FH, discussion between and within families, and timely referrals to genetic testing. The gene discussed is BRCA2; the disease is cancer.